Received Dec 22, 2025
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| MENB | MENINGOCOCCAL B (BEXSERO) | NOVARTIS VACCINES AND DIAGNOSTICS | UNK | 3R33K | RA |
A local reaction Redness; This non-serious case was reported by a nurse via sales rep and described the occurrence of localized erythema in a 21-year-old female patient who received Men B NVS (Bexsero) (batch number 3R33K, expiry date 31-AUG-2028) for prophylaxis. Concurrent medical conditions included attention deficit hyperactivity disorder, depression and anxiety. Concomitant products included amfetamine aspartate, amfetamine sulfate, dexamfetamine saccharate, dexamfetamine sulfate (Adderall), sertraline hydrochloride (Zoloft) and ethinylestradiol, norgestimate (Estarylla). On 27-OCT-2025, the patient received Bexsero (right arm). On 27-OCT-2025, less than a day after receiving Bexsero, the patient experienced localized erythema (Verbatim: A local reaction Redness). On 29-OCT-2025, the outcome of the localized erythema was resolved (duration 2 days). The reporter considered the localized erythema to be unrelated to Bexsero. It was unknown if the reporter considered the localized erythema to be related to Bexsero Pre-Filled Syringe Device. The company considered the localized erythema to be unrelated to Bexsero. It was unknown if the company considered the localized erythema to be related to Bexsero Pre-Filled Syringe Device. This report is made by GSK without prejudice and does not imply any admission or liability for the incident or its consequences.
Anxiety; Attention deficit hyperactivity disorder; Depression
ADDERALL; ZOLOFT; ESTARYLLA